RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, we have shown that the increased H19/miR-675-5p levels contribute to imatinib resistance in CML cells through regulation of RUNX1 expression, and newly identified LNC000093 serves as a ceRNA for miR-675-5p with functionally significant effects.